Mesenchymal stem cells from amniotic fluid for treating congenital and other diseases

Research output: Chapter in Book/Report/Conference proceedingChapter


Over the past decade, amniotic fluid-derived mesenchymal stem/stromal cells (AF-MSCs) have emerged as a novel, experimental approach for the treatment of a wide variety of congenital anomalies diagnosed either in utero or postnatally. This article gives a pediatric surgeon’s perspective on AF-MSC therapy for the management of congenital anomalies and other diseases. The current status in preterm AF-MSC research, particularly as it relates to tissue engineering-based applications, is described in various experimental animal models. A roadmap for further study and eventual clinical application is also proposed.

Original languageEnglish (US)
Title of host publicationEncyclopedia of Tissue Engineering and Regenerative Medicine
Number of pages8
ISBN (Electronic)9780128136997
ISBN (Print)9780128137000
StatePublished - Jan 1 2019
Externally publishedYes


  • Amniocytes
  • Amniotic fluid
  • Congenital anomalies
  • Fetal therapy
  • Fetus
  • Induced pluripotent stem cells
  • Mesenchymal stem cells
  • Stem cell therapy
  • Stem cells
  • Tissue engineering

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Mesenchymal stem cells from amniotic fluid for treating congenital and other diseases'. Together they form a unique fingerprint.

Cite this